Net Income

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

The sustainable materials firm saw net income jump 60% after a planned shutdown created a record backlog, setting the stage for a strong Q3.

With a massive capital raise and rapid microreactor progress, NANO Nuclear is positioning itself to power the AI boom and lead a new nuclear renaissance.

WhiteFiber lands a 10-year, 40 MW anchor deal with AI provider Nscale, validating its high-density strategy and fueling North Carolina's tech boom.

As Applied Digital preps its Q2 results, investors watch to see if its multi-billion dollar contracts can quell market volatility and affirm its AI future.

The U.S. government is partnering with 24 tech leaders, including Accenture, on a mission to double R&D and secure global leadership in AI.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

National homebuilder Toll Brothers opens Bethany Farms in Simpsonville, tapping into the area's hot luxury market with customizable homes and amenities.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Millions struggle to swallow pills. Azurity's new FDA-approved liquid hypertension drug, Javadin, offers a ready-to-use solution for better adherence.

European FinTech Multitude AG unveils its 2026 financial calendar, offering investors a clear roadmap amid strong growth and evolving market dynamics.

Medical cannabis firm Crucial Innovations retains FOCUS Capital Partners, signaling a push for institutional investment and a potential 2026 US listing.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

Syra Health appoints Gregory R. Alexander as CEO, banking on his military discipline and record of scaling healthcare firms to drive its next growth phase.

Formerly a green housing developer, the company is now RenX Enterprises, betting its future on the multi-billion dollar market for sustainable soils.

The AI defense firm's stock surged after announcing a share repurchase, a move reflecting deep internal confidence amid a booming defense-tech market.

Facing market pressure, Mobileye plans a major CES 2026 reveal of its 'physical AI' and new chip architecture alongside key partner Volkswagen.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.